Epidemiology and etiology of diabetic peripheral neuropathies

Advanced Studies in Medicine

Volumn 4, Issue 10 G, 2004, Pages

  Tesfaye, Solomon ^a,b  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDOSE REDUCTASE INHIBITOR; AMANTADINE; ANTICONVULSIVE AGENT; CAPSAICIN; DIACYLGLYCEROL; ISOSORBIDE DINITRATE; LIDOCAINE; MEXILETINE; PROTEIN KINASE C; RUBOXISTAURIN; THIOCTIC ACID; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLODYNIA; BODY MASS; BURNING SENSATION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CONFERENCE PAPER; DIABETIC NEUROPATHY; DISEASE COURSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG TOLERABILITY; ENDOTHELIUM LESION; EVALUATION; FOOT ULCER; GENETIC DISORDER; GLUCOSE BLOOD LEVEL; HUMAN; HYPOXIC CELL; MICROANGIOPATHY; NERVE CELL; NERVE INJURY; PAIN; PAIN ASSESSMENT; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRICK TEST; PROPRIOCEPTION; RISK FACTOR; SIDE EFFECT; SKIN SENSITIVITY; SKIN TINGLING; SYMPTOMATOLOGY;

EID: 11244290126     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Thomas PK. Diabetic peripheral neuropathies: their cost to patient and society and the value of knowledge of risk factors for development of interventions. Eur Neurol. 1999; 41(suppl 1):35-43.
2. Duby JJ, Campbell RK, Setter SM, et al. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm. 2004;61:160-173.
3. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26:1790-1795.
4. Boulton AJ. The diabetic foot: o global view. Diabetes Metab Res Rev. 2000;16(suppl 1):S2-S5.
5. Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002;19:377-384.
6. Reiber GE. The epidemiology of diabetic foot problems. Diabet Med. 1996;13(supp 1):S6-S11.
7. Muller IS, de Grauw WJ, van Gerwen WH, et al. Foot ulceration and lower limb amputation in type 2 diabetic patients in Dutch primary health care. Diabetes Care. 2002;25:570-574.
8. Boyko EJ, Ahroni JH, Smith DG, Davignon D. Increased mortality associated with diabetic foot ulcer. Diabet Med. 1996;13:967-972.
9. Boulton AJM, ed. Diabetic Neuropathy. Bridgewater, NJ: Aventis Pharma; 2001.
10. Boulton AJM. The diabetic foot. In: Pickup JC, Williams G, eds. Textbook of Diabetes. 2nd ed. Oxford, UK; Cambridge, Mass: Blackwell Science; 1997.
11. Quattrini C, Tesfaye S. Understanding the impact of painful diabetic neuropathy. Diabetes Metab Res Rev. 2003; 19(suppl 1):S2-S8.
12. Tesfaye S, Stephens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39:1377-1384.
13. Tesfaye S, Chaturvedi N, Eaton SM, et al. Cardiovascular risk factors predict development of diabetic peripheral neuropathy. Diabetes Res Clin Pract. 2000;50:274.
14. Forsblom CM, Sane T, Groop PH, et al. Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia. 1998;41:1253-1262.
15. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologio. 2001;44:1973-1988.
16. Gabbay KH, Merola LO, Field RA. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science. 1966;151:209-210.
17. Tomlinson DR, Moriarity RJ, Mayer JH. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil. Diabetes. 1984;33:470-476.
18. Judzewitsch RG, Jaspan JB, Polonsky KS, et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med. 1983;308:119-125.
19. Simo AA, Bril V, Nathaniel V, et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med. 1988;319:548-555.
20. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenprestat Study Group [published correction appears in Neurology. 2001;56:1124]. Neurology. 1999;53:580-591.
21. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenprestat Study Group [published correction appears in Neurology. 2001;56:1124]. Neurology. 1999;53:580-591.
22. Malik RA, Tesfaye S, Thompson SD, et al. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia. 1993;36:454-459.
23. Newrick PG, Wilson AJ, Jakubowski J, et al. Sural nerve oxygen tension in diabetes. Br Med J (Clin Res Ed). 1986;293:1053-1054.
24. Tesfaye S, Harris N, Jakubowski JJ, et al. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluoroscein angiography. Diabetologia. 1993;36:1260-1274.
25. Tesfaye S, Harris ND, Wilson RM, Ward JD. Exercise-induced conduction velocity increment: a marker of impaired peripheral nerve blood flow in diabetic neuropathy. Diabetologia. 1992;35:155-159.
26. Tesfaye S, Malik R, Harris N, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia. 1996;39:329-335.
27. Eaton SE, Harris ND, Ibrahim S, et al. Increased sural nerve epineuria blood flow in human subjects with painful diabetic neuropathy. Diabetologia. 2003;46:934-939.
28. Young MJ, Veves A, Smith JV, et al. Restoring lower limb blood flow improves conduction velocity in diabetic patients. Diabetologia 1995;38:1051-1054.
29. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care. 2002;25:2048-2052.
30. Smieja M, Hunt DL, Edelman D, et al. Clinical examination for the detection of protective sensation in the feet of diabetic patients. International Cooperative Group for Clinical Examination Research. J Gen Intern Med. 1999;14:418-424.
31. Rith-Najarian SJ, Stolusky T, Gohdes DM. Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria. Diabetes Care. 1992;15:1386-1389.
32. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001;24:250-256.
33. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care. 1994; 17:557-560.
34. Abbott CA, Vileikyte L, Williamson S, et al. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care. 1998;21:1071-1075.
35. Coppini DV, Bowtell PA, Weng C, et al. Showing neuropathy is related to increased mortality in diabetic patients: a survival analysis using an accelerated failure time model. J Clin Epidemiol. 2000;53:519-523.
36. Dyck PJ, Zimmerman I, Gillen DA, et al. Cool, warm, and heat-pain detection thresholds: testing methods and inferences about anatomic distribution of receptors. Neurology. 1993;43:1500-1508.
37. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831-1836.
38. Harati Y, Gaoch C, Swensan M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842-1846.
39. Tesfaye S, Watt J, Benbow SJ, et al. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet. 1996;348:1698-1701.
40. Eaton SE, Harris ND, Rajbhandari SM, et al. Spinal-cord involvement in diabetic peripheral neuropathy. Lancet. 2001;358:35-36.
41. Selvarajah D, Wilkinsan ID, Griffiths PD, et al. Abnormal thalamic resonance spectroscopy: evidence for functional impairment of the thalamus in diabetic neuropathy. Diabet Med. 2004;21(suppl 2):abstract.
42. Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial [published correction appears in Diabetes Care. 2003;26:2227]. Diabetes Care. 2003;26:770-776.
43. Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial [published correction appears in Diabetes Care. 2003;26:2227]. Diabetes Care. 2003;26:770-776.
44. Litchy W, Dyck W, Tesfaye S, et al. Diabetic peripheral neuropathy (DPN) assessed by neurologica examination (NE) and composite scores (CS) is improved with LY333531 treatment. Diabetes. 2002;51(suppl 2):A197.
45. Vinik AI, Tesfaye S, Zhang D, et al. LY333531 treatment improves diabetic peripheral neuropathy (DPN) with symptoms. Diabetes. 2002;51(suppl 2):A79.